依洛尤单抗治疗伴有实体器官移植的囊性纤维化患者的疗效。
Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.
机构信息
Department of Infectious Diseases, Cystic Fibrosis Clinic, Aarhus University Hospital, Aarhus, Denmark.
Department of Cardiology, Section for Lung Transplantation, University Hospital Rigshospitalet Copenhagen, Kobenhavn, Denmark.
出版信息
Pediatr Pulmonol. 2023 Feb;58(2):602-605. doi: 10.1002/ppul.26217. Epub 2022 Nov 11.
PMID:36314653
Abstract
We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.
摘要
我们报告了四例囊性纤维化 (CF) 患者的病例系列，这些患者在接受 elexacaftor/tezacaftor/ivacaftor 治疗 6 个月或更长时间之前曾接受过实体器官移植 (SOT)。数据是回顾性收集的。该治疗耐受性良好，所有患者均报告主观改善。
Zotero 插件